Dnca Finance Sells 2,000 Shares of Thermo Fisher Scientific Inc. $TMO

Dnca Finance decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,950 shares of the medical research company’s stock after selling 2,000 shares during the quarter. Dnca Finance’s holdings in Thermo Fisher Scientific were worth $8,494,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CBIZ Investment Advisory Services LLC boosted its holdings in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at approximately $31,000. DiNuzzo Private Wealth Inc. raised its holdings in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after buying an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after acquiring an additional 45 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $572.49 on Friday. The firm has a market cap of $215.09 billion, a PE ratio of 33.07, a price-to-earnings-growth ratio of 4.19 and a beta of 0.90. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The business’s 50 day moving average price is $559.70 and its two-hundred day moving average price is $485.50.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific announced that its board has approved a stock repurchase program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TMO. Barclays raised their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. William Blair assumed coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Evercore ISI lifted their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Wells Fargo & Company increased their target price on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $602.35.

Insiders Place Their Bets

In related news, COO Michel Lagarde sold 22,046 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the transaction, the chief operating officer directly owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. This represents a 20.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Lisa P. Britt sold 1,058 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the sale, the vice president owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 149,271 shares of company stock worth $86,507,282 over the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.